Asian Journal of Psychiatry
April 1, 2025
Asif Seraj, Mohammed Reyazuddin, R K Gaur et al.
11 citations
The simplest, most convenient, and least expensive way to treat depressed and suicidal patients with ketamine is to administer racemic ketamine by the oral route. We describe the first active-controlled randomized clinical trial of oral racemic ketamine for suicidal ideation associated with depression. Adult patients with major depressive disorder and expressed suicidal ideation were randomized...
Acta Psychiatrica Scandinavica
December 3, 2024
Vikas Menon, Parthasarathy Ramamurthy, Sandesh Venu et al.
15 citations
ABSTRACT Introduction There is growing interest in the use of psychedelic‐assisted therapy (PAT) for major depressive disorder (MDD), including treatment‐resistant depression. We used randomized controlled trial (RCT) data to compare summary estimates of change in depression ratings with PAT versus comparator treatments in MDD. We also compared response and remission rates, and adverse effects....
Asian Journal of Psychiatry
September 1, 2024
Pn Suresh Kumar, Vikas Menon, Chittaranjan Andrade
12 citations
For depression, ketamine is more conveniently administered by oral than by intravenous (iv) routes. The relative antidepressant efficacy of oral vs iv ketamine is unknown. To assess the acute efficacy and the persistence of improvement with open-label oral versus iv ketamine in outpatients with treatment-resistant depression (TRD). Adults with TRD were randomized to oral (N=30) or IV (N=31)...
Indian Journal of Psychiatry
September 1, 2024
Harsimar Kaur, Chittaranjan Andrade
3 citations
Dear Editor, Ketamine is used off-label for indications ranging from depression to chronic pain. We know of no report of the successful use of oral ketamine, administered without psychotherapy, for complex posttraumatic stress disorder (cPTSD).[1,2] We describe a patient with chronic depression and cPTSD who failed >30 previous interventions but had dramatic and persistent relief from chronic...
JAMA Psychiatry
December 1, 2023
Chittaranjan Andrade
This Viewpoint discusses ketamine and its new and experimentally investigated on- and off-label indications that span different medical disciplines.
Acta Psychiatrica Scandinavica
September 17, 2023
Chittaranjan Andrade
5 citations
It is almost axiomatic with most drugs and for most disorders in psychiatry that whatever elicits response and remission during the acute phase of illness will prevent relapse and recurrence of illness during the maintenance phase of treatment. Logically, this principle should apply to ketamine, as well, when the drug is used for patients with depression; thus, at the very least, the treatment,...
JAMA Psychiatry
June 1, 2023
Vikas Menon, Natarajan Varadharajan, Abdul Faheem et al.
50 citations
ImportanceThe relative efficacy of ketamine and electroconvulsive therapy (ECT) in adults with major depressive episode (MDE) needs clarification.ObjectiveTo compare depression rating outcomes with ketamine vs ECT in adults with MDE and to compare response and remission rates, number of sessions to response and remission, and adverse effects.Data SourcesTwo investigators independently...
The Journal of Clinical Psychiatry
2018
Chittaranjan Andrade
A growing body of literature suggests that ketamine, administered in subanesthetic doses, has early-onset antidepressant action in patients with severe and even treatment-refractory depression. Many case reports, open-label studies, and randomized controlled trials (RCTs) suggest that ketamine may have dramatic antisuicidal effects, as well. This article examines the benefits of ketamine in...
The Journal of Clinical Psychiatry
December 27, 2017
Chittaranjan Andrade
Article AbstractBecause this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.To the Editor: Dr Bartoli and colleagues suggest that the dissociative and antidepressant effects of ketamine are two sides of the same coin or, to use a different metaphor, that they go hand in hand. This is hardly surprising. The efficacy and adverse effects...
The Journal of Clinical Psychiatry
July 20, 2017
Chittaranjan Andrade
179 citations
BACKGROUND: Ketamine, administered in subanesthetic doses, is an effective off-label treatment for severe and even treatment-refractory depression; however, despite dozens of studies across nearly 2 decades of research, there is no definitive guidance on matters related to core practice issues. METHODS: This article presents a qualitative review and summary about what is known about ketamine...
The Journal of Clinical Psychiatry
June 27, 2017
Chittaranjan Andrade
80 citations
Ketamine is a racemic mixture of the enantiomers R-ketamine and S-ketamine (esketamine). S-ketamine has greater analgesic and anesthetic effects than R-ketamine and is less likely to cause psychotomimetic and other adverse effects. There is therefore an emerging interest favoring the use of S-ketamine over racemic ketamine when the drug is used for analgesia or anesthesia. This article examines...
The Journal of Clinical Psychiatry
April 2017
Chittaranjan Andrade
Ketamine is an anesthetic drug that is also used for off-label indications such as the mediation of analgesia and sedation in various settings. It is additionally recognized as an agent with antidepressant potential. For depression, it is most commonly administered as a slow intravenous infusion in subanesthetic doses (usually 0.5 mg/kg). As an antidepressant, is strikingly different from...
The Journal of Clinical Psychiatry
June 22, 2016
Chittaranjan Andrade
19 citations
Psychosis is one of the most serious among the adverse effects associated with cannabis use. The association between cannabis use and psychosis has been variously explored in a series of recent meta-analyses. The results of these meta-analyses show that persons who develop psychosis experience onset of psychosis about 2-3 years earlier if they are cannabis users; this effect is not observed...
The Journal of Clinical Psychiatry
May 2015
Chittaranjan Andrade
Intranasal drug delivery (INDD) systems offer a route to the brain that bypasses problems related to gastrointestinal absorption, first-pass metabolism, and the blood-brain barrier; onset of therapeutic action is rapid, and the inconvenience and discomfort of parenteral administration are avoided. INDD has found several applications in neuropsychiatry, such as to treat migraine, acute and...
Indian Journal of Psychiatry
April 1, 2010
T. Rao, Chittaranjan Andrade
Byline: T.S. Rao, Chittaranjan. Andrade Antidepressant drugs have traditionally addressed the monoamine triumvirate: serotonin, noradrenaline, and dopamine. There have been predominantly two mechanisms recruited in drug action - inhibition of monoamine reuptake and inhibition of intravesicular monoamine catabolism. Tianeptine, which increases the synaptic reuptake of serotonin, and mirtazapine,...